CBD and CBG in New Research Findings
Summarize
A new research project points to an unexpected source in the study of chronic liver disease: cannabis-derived compounds. A recent study from the Hebrew University of Jerusalem, published in the British Journal of Pharmacology, evaluated two non-intoxicating cannabinoids in a liver-related metabolic research setting. They are cannabidiol (CBD) and cannabigerol (CBG).
The study focused on a common metabolic condition linked to obesity. It affects a large number of adults worldwide and remains a widely studied topic. In this project, researchers used the condition as a model to evaluate CBD and CBG in an experimental setting. Current management approaches are often centered on lifestyle changes, including weight loss and dietary adjustments.
Working at the Cellular Level
CBD is already familiar to the medical and wellness communities. CBG is not as well researched, even though it is known as the “mother of all cannabinoids.” CBG is a precursor cannabinoid in the cannabis plant. During the research project, which involved experimental models, researchers evaluated CBD and CBG in relation to liver-associated metabolic changes. Since neither cannabinoid produces psychoactive effects, they may be of interest for further study.
What distinguishes this research is its identification of how these compounds work at a cellular level. The researchers describe a process called “metabolic remodeling,” in which CBD and CBG enhance the liver’s ability to manage energy. Specifically, they were studied in relation to phosphocreatine levels. Phosphocreatine is a compound that rapidly increases the body’s energy reserve in the brain and muscles. This acts like a backup energy reserve, helping sustain cellular activity under metabolically challenging conditions.
The study also found improvements in the liver’s internal waste management systems. CBD and CBG were associated with cathepsin-related activity, which helps break down and recycle cellular waste. This process enables the liver to more effectively clear harmful lipids, including triglycerides and ceramides, both of which are linked to disease progression.
While both cannabinoids delivered measurable benefits, CBG stood out in several areas. In the experimental models, it was associated with greater changes in body composition and metabolic markers.
Creating a New Research Direction
Despite the promising findings, researchers state that these results are preliminary. The study was conducted in controlled experimental settings, not in human clinical trials. Much more clinical research is needed on the effects of cannabinoids on different medical conditions.
Currently, the most established cannabinoid-related uses remain limited to a small number of FDA-approved prescription products. This project adds to a growing area of research by examining liver-related metabolic processes, with a particular focus on cellular energy and waste-processing pathways. Any broader conclusions about the role of CBD and CBG will depend on future clinical research in humans.
Ongoing Research on Cannabinoids
The science is still evolving, but studies like these point to a shift in medicine. Researchers are increasingly investigating cannabinoids, and this study took research to a new level by focusing on how a cannabis-derived therapy may impact the metabolic system and not just symptoms. Of course, the real test will be human trials.
Share this post
0